Anticuerpos antifosfolipídicos y niveles beta 2 microglubulina en grupo de pacientes con lupus eritematoso sistémico

Flores, María; Chacón de P., María; Pacheco, Mariela; Castro, Liliana; Varela, Indira; Valera, Carolina; Zambrano, Bella.
Salus ; 3(1): 32-39, abr. 1999. tab
Artigo em Espanhol | LILACS | ID: lil-502431

Documentos relacionados

  1. [The analysis to data from Chinese Rheumatism Data Center external quality assurance program for autoantibodies in 2021].
  2. Antibodies to Domain I ß<sub>2</sub>-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus.
  3. Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis.
  4. Clinical significance of IgA anti-cardiolipin and IgA anti-ß2glycoprotein I antibodies.
  5. Non-Criteria or Seronegative Obstetric Antiphospholipid Syndrome?
  6. Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-ß2-glycoprotein I antibodies: a systematic evaluation according to the guidelines.
  7. Validation of a New Panel of Automated Chemiluminescence Assays for Anticardiolipin Antibodies in the Screening for Antiphospholipid Syndrome.
  8. [Comments on antiphospholipid antibody tests].
  9. A new Eu(3+)-labeled method for anticardiolipin antibody IgM.
  10. Lupus anticoagulants: pathogenesis and laboratory diagnosis.